Quality of Life Measures in Patients With Retinal Degeneration
Launched by UNIVERSITY OF OXFORD · Jun 24, 2016
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
IRD presents a significant burden on the NHS as well as on the individual and families. IRDs are particularly difficult in a family situation due to guilt and other complex emotions related to inheritance patterns. Poorer mental health has been reported in patients with retinitis pigmentosa, manifesting in a range of ways including stress, depression and anxiety, particularly as the disease progresses. This is most probably caused by the uncertainty of the disease process and the progressive nature of the degeneration.
Recent work has reported that quality of life significantly deteriorate...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participant is willing \& able to give informed consent for participation in the study.
- • Male or female, aged 18 - 85.
- • A clinical or genetic diagnosis of retinal degeneration or normal age and sex-matched controls without known retinal disease.
- • Able to participate in visual function testing.
- Exclusion Criteria:
- * The participant may not enter the study if any of the following apply:
- • 1) they have a pre-existing amblyopia or squint;
- • 2) they have any other retinal problems that may confound the measures assessed.
About University Of Oxford
The University of Oxford, a prestigious institution renowned for its excellence in research and education, serves as a leading clinical trial sponsor dedicated to advancing medical science and improving patient care. With a rich history of innovation and a multidisciplinary approach, the university leverages its extensive expertise in various fields, including medicine, public health, and biomedical research, to conduct rigorous clinical trials. Collaborating with healthcare professionals, industry partners, and regulatory bodies, the University of Oxford aims to translate groundbreaking research findings into effective therapies and interventions, contributing to the global effort of enhancing health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oxford, , United Kingdom
Patients applied
Trial Officials
Jasleen K Jolly, MSc
Principal Investigator
University of Oxford
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials